Related posters
(Kineta) A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors
anti-hVISTA against poorly immunogenic tumors
April 10, 2021
Background
- VISTA (V-domain Ig Suppressor of T cell Activation) is a unique B7 family member, mainly expressed on myeloid cells, neutrophils, NK cells and Treg
- VISTA is highly expressed on MDSC and Treg in the TME and play an important role in immune modulation
- VISTA is a negative regulator that directly suppresses T-cell activation and proliferation
- High VISTA expression correlates with poor survival in cancer patients
- VISTA is a unique Immune checkpoint inhibitor for tumor immunotherapy
Conclusion
- 107 fully human ScFv anti-VISTA antibodies were generated and analyzed
- Kineta’s anti-VISTA lead antibody is highly specific
- Kineta’s anti-VISTA lead antibody activates monocytes, and this activation is NK dependent
- Kineta’s anti-VISTA lead antibody reverse MDSC suppression of T cells
- Kineta’s anti-human VISTA lead antibody induces strong anti-tumor response as a single agent or in combo-therapies with anti-PDL1 or anti-CTLA4 in different hard to treat tumor models
- KVA 12.1 is our lead antibody for IND enabling studies.
Scientific excellence
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Robust validation data on catalog models
Comprehensive dataset package
Generated with biopharma partners and in-house
Customer care
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Easy and fast access to models
Breeding facilities in US and Europe
Certified health status from professional breeders